Bioavailability of ergoloid mesylates liquid capsule.

Area of Science:

• Pharmacology
• Clinical Pharmacy
• Drug Formulation

Background:

• Ergoloid mesylates are used for various conditions.
• Understanding formulation bioavailability is crucial for therapeutic efficacy.
• Comparing liquid capsules and oral tablets is important for drug delivery.

Purpose of the Study:

• To compare the bioavailability of two ergoloid mesylates formulations.
• To determine if liquid capsules and oral tablets are bioequivalent.
• To assess pharmacokinetic parameters of ergoloid mesylates formulations.

Main Methods:

• A randomized, crossover study involving 18 healthy men.
• Administration of single oral doses of liquid capsules and oral tablets (1 mg each).
• Radioimmunoassay to measure plasma ergoloid mesylates concentrations over 10 hours.

Main Results:

• Liquid capsules yielded approximately 12% higher mean peak concentrations and AUC compared to oral tablets (P < 0.05).
• No significant differences were found in time to peak concentration, absorption/elimination rates, or lag time.
• Despite statistical significance, differences were below 20%, meeting FDA bioequivalence guidelines.

Conclusions:

• The two ergoloid mesylates formulations (liquid capsule and oral tablet) are considered bioequivalent.
• The clinical significance of the observed bioavailability difference requires further investigation.
• Further studies are needed to establish the therapeutic benefit of the liquid capsule formulation.